It has been shown that KMO inhibitors (Ro61-804 and its prodrug JM6) are neuroprotective in ischemia (Röver et al., 1997; Moroni et al., 2005), dyskinesia (Grégoire et al., 2008), Alzheimer’s disease (Chin et al., 2005), and Huntington’s disease (Zwilling et al., 2011) and that they are able to diminish the activation of microglia and, as a consequence, the production of cytokines (Croitoru-Lamoury et al., 2003; Chin et al., 2005). This evidence concerns the gene KMO and drug-induced dyskinesia.